Recent Updates
Recently added Catalysts

PF-07868489

Phase 2

Pulmonary Hypertension | Small molecule | Cardiovascular |Pfizer, Inc.|Last Updated: May 19, 2026

Success Probability
Subscribe to view
Market & Valuation
Subscribe to view
Trial Design
UNCONTROLLED
Total Trials1
Total Enrollment36
FDA Designations
No designations recorded
Clinical trial landscape

PF-07868489 · 2 trials · 2 indications

Phase 2 1Phase 1 1
NCT07073820A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489Pulmonary Hypertension
RECRUITING36 Analytics
PHASE2RECRUITING
A Study to Learn About the Study Medicine (Called PF-07868489) in People With Pulmonary Arterial Hypertension Who Have Previously Participated in a Clinical Study With PF-07868489
Pulmonary Hypertension
NCT0707382036
Unlock trial analytics
Study Endpoints
Primary Endpoints
Number of Participants with Treatment Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)
Baseline up to week 111
Number of Participants With Change From Baseline in Laboratory Tests Results
Baseline up to week 111
Number of Participants With Vital Sign Abnormalities
Baseline up to week 111
Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters
Baseline up to Day 113

Part A

Change From Baseline in Pulmonary Vascular Resistance (PVR) at Week24
Baseline, Week 24

repeated doses

Secondary Endpoints
Number of Participants With Change From Baseline in Electrocardiogram (ECG) Parameters
Baseline up to week 111
Change From Baseline in N-Terminal Prohormone Brain Natriuretic Peptide (NT-proBNP) Concentration
Baseline up to week 104
Minimum Observed Plasma Trough Concentration (Cmin), as data permits
Baseline up to week 111
Unlock Study Endpoints
Study Design & Arms
AllocationNA
MaskingNONE
ModelSINGLE_GROUP
PurposeTREATMENT
Treatment Arms
ArmTypeDescription
Open LabelEXPERIMENTALParticipants will receive subcutaneous doses of PF-07868489 every 4 weeks
PF-07868489EXPERIMENTALsingle subcutaneous injection (Part A); 6 subcutaneous injections at regular intervals (Part B)
PlaceboPLACEBO_COMPARATORsingle subcutaneous injection (Part A); 6 subcutaneous injections at regular intervals (Part B)
Interventions
NameTypeDescription
PF-07868489DRUGParticipants will receive subcutaneous doses of PF-07868489 every 4 weeks
Placebo for PF-07868489DRUGPlacebo
Unlock Study Design Details
Eligibility Criteria
Age Range18 Years to N/A
SexALL
Healthy VolunteersNo
Study Sites48

This study is seeking participants who are: * aged 18 years or older at screening of the previous study and completed the required treatment duration with PF-07868469 and other assessments at the end of that study. * willing and able to abide with all scheduled visits, treatment plan, laboratory te...

Countries:United StatesAustraliaBelgiumCanadaChinaCzechiaFranceGermanyGreeceItalyJapanSouth KoreaSpainUnited Kingdom
Unlock Eligibility Criteria
Competitive Landscape -Pulmonary Arterial Hypertension 40 trials (matched to "Pulmonary Hypertension")
CompanyTickerTrialsLead PhaseDrugs
United Therapeutics CorporationUTHR5PHASE3Ralinepag
Merck & Co., Inc.MRK6PHASE3Riociguat
Insmed IncorporatedINSM4PHASE3Treprostinil Palmitil
Johnson & JohnsonJNJ4PHASE3Selexipag
Liquidia CorporationLQDA4PHASE3L606
Tenax Therapeutics, Inc.TENX3PHASE3TNX-103
Gossamer Bio, Inc.GOSS2PHASE3Seralutinib
Inhibikase Therapeutics, Inc.IKT1PHASE3IKT-001
Regeneron Pharmaceuticals, Inc.REGN1PHASE2REGN13335
Pfizer Inc.PFE2PHASE2PF-07868489
Tectonic Therapeutic IncTECX1PHASE2TX000045- Dose A, TX000045- Dose B
Abbott LaboratoriesABT1N/AUndisclosed
Third Pole Therapeutics, Inc.THRD1N/AUndisclosed
Unlock Competitive Intelligence
Recent Changes (Last 90 Days)
LOWMay 26, 2026NCT07073820primaryCompletionDate: changed
LOWMay 26, 2026NCT06137742Enrollment: 96 → 97
LOWMay 24, 2026NCT07073820studyFirstPostDate: changed
LOWMay 24, 2026NCT06137742studyFirstPostDate: changed